Editas Medicine (NASDAQ:EDIT) is one of the best gene-editing stocks to buy according to hedge funds. On November 10, 2025, Clear Street raised its price target on Editas Medicine (NASDAQ:EDIT) to $4.60 from $4.00, while maintaining a Buy rating. The firm highlighted the company’s extended cash runway into the third quarter of 2027, supported by recent fundraising, and reaffirmed confidence in Editas’ lead program EDIT‑401, a gene editing therapy targeting LDL cholesterol.
Editas strengthened its balance sheet by raising $17.8 million through its ATM (at-the-market) offering in the third quarter and an additional $17.3 million in the fourth quarter, bringing its pro forma cash balance to $183 million. Clear Street noted this runway now extends beyond initial human data for EDIT‑401, providing financial flexibility to advance development milestones.
On the same day, Editas reported Q3 2025 results, posting EPS of –$0.28, slightly better than analyst estimates. Revenues rose to $7.5 million from $0.1 million in Q3 2024, driven by milestone recognition under its collaboration with Bristol Myers Squibb. CEO Gilmore O’Neill emphasized progress with EDIT‑401, citing preclinical data presented at AHA and ESGCT showing over 90% LDL cholesterol reduction in non‑human primates.
Editas Medicine is a pioneering gene editing company focused on developing transformative in vivo therapies using CRISPR technology. Its pipeline includes EDIT‑401, with plans to file for IND/CTA by mid‑2026 and achieve human proof‑of‑concept data by year‑end 2026. The company holds exclusive licenses to the Broad Institute’s Cas12a and Cas9 patent estates, positioning it as a leader in precision gene editing.
READ NEXT: 10 Best European Bank Stocks to Buy Now and 11 Best Solar Energy Stocks to Buy Right Now.
This article is originally published at Insider Monkey.
